Emyria (EMD) investor relations material

FY26 growth and clinic footprint

• FY26 revenue rose 191% to A$4.05m from A$1.39m; revenue was A$4.3m including a A$0.2m tax grant.

• Clinic count grew from 1 to 5 and beds from 4 to 18; FY26 clinic count includes announced sites not yet operational.

• FY26 total patients treated reached 138 vs 24; ~145 clinicians trained vs ~30, and 17 authorised prescribers vs 4.

• Latest operating snapshot lists clinics across four states and more than 160 patients treated since services commenced.

Clinical reach and treatment access

• Treatments target PTSD and treatment-resistant depression; 12-month PTSD outcomes and early TRD data were announced.

• Medibank became the first private health insurer to fund treatments; first Department of Veterans’ Affairs approvals were secured.

• Sites opened in Perth, Brisbane, Mornington and Sydney; a second Perth clinic was also opened.

Strategic growth opportunities

• Former US Veterans Affairs Secretary Dr David Shulkin joined as strategic advisor in September 2026 to support US federal healthcare and veterans’ health opportunities.

• Priorities include clinical and research partnerships, health-system and government engagement, and partnerships with drug developers needing specialist clinical delivery.

• Future drivers include confirmed sites, a second Empax Global Partnership Program partner, maturing clinic utilisation, new funders and additional treatable conditions.